| This week's sponsor is TD2. | |  | |
Featured Story | | | Monday, September 25, 2017 In a first for the Big Pharma and as part of a new model, Pfizer is taking drugs from its shelves and licensing them to, while investing in, its SpringWorks Therapeutics startup. |
|
|
| This week's sponsor is FierceBiotech. | |  | FierceBiotech Executive Summit- London
Join FierceBiotech for our third annual Executive Summit in London. We'll gather the experts together to discuss innovation around R&D in the UK and look ahead to what's in store for 2018 with leaders in the field discussing trends in the industry. |
Top Stories Monday, September 25, 2017 The FDA has delivered its expected rejection of Johnson & Johnson’s rheumatoid arthritis drug sirukumab. J&J is now assessing what it will take to quell the agency’s concerns about the safety of the IL-6 monoclonal antibody before deciding on a path forward. Monday, September 25, 2017 AstraZeneca has struck a deal to combine its anti-PD-L1 drug with NewLink Genetics’ IDO pathway inhibitor. The collaborators will jointly fund a phase 2 trial of the combination in pancreatic cancer patients. Monday, September 25, 2017 RBM shouldn’t be a point of concern, but rather a point of validation of what matters. It’s, above all, an opportunity to practice mindfulness in collecting clinical trial data within the site-and patient-centric environment. Monday, September 25, 2017 With a positive phase 3 trial in hand, Japan’s Daiichi Sankyo plans to file its essential hypertension therapy esaxerenone in its home market next year. Monday, September 25, 2017 Gelesis has claimed success in a pivotal trial of its obesity candidate. More than half of participants who took the swelling hydrogel particles lost weight, encouraging Gelesis to file for approval despite missing the other co-primary endpoint. Monday, September 25, 2017 Scientists at the National Institute of Standards and Technology have created a rapid test that indicates if an antibiotic fights a given infection, which could speed up treatments and reduce improperly prescribed antibiotics. Monday, September 25, 2017 Bristol-Myers Squibb’s Opdivo has won another FDA approval—and the right to take on Bayer in liver cancer. The immuno-oncology standout is now cleared for patients who've already been treated with Bayer’s Nexavar, the same group targeted by the German drugmaker's follow-up drug Stivarga. | This week's sponsor is CMed. | |  | |
Resources Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: Ashfield Healthcare Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. Presented By: PRA Health Sciences Children participating in pediatric clinical trials are included in the contraceptive requirements applied to women of child-bearing potential, creating significant challenges for sponsors, parents, investigators and study staff. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
